Ultimovacs - Positive Phase I update in malignant melanoma
Ultimovacs has announced positive three-year data from the UV1-103 Phase I trial (n=30) assessing UV1 in combination with pembrolizumab for the treatment of malignant melanoma. Of the participants that agreed to long-term monitoring, an overall survival (OS) rate of 67% (18/27) was reported at three years. While we caution against direct read across, and acknowledge there are differences in study designs, we highlight that pembrolizumab showed an OS rate of 51% at three years in the registrational KEYNOTE-006 study. We also note that UV1-103 treats the same patient population as Ultimovacs’ INITIUM Phase II trial, and top-line results are expected in H223, representing a significant upcoming catalyst.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.